These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 28992881)

  • 1. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Zhao RC; Zhou J; Wei YG; Liu F; Chen KF; Li Q; Li B
    Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):493-498. PubMed ID: 28992881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.
    Chen S; Peng Z; Wei M; Liu W; Dai Z; Wang H; Mei J; Cheong M; Zhang H; Kuang M
    BMC Cancer; 2018 Apr; 18(1):392. PubMed ID: 29621988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.
    Thein HH; Qiao Y; Zaheen A; Jembere N; Sapisochin G; Chan KKW; Yoshida EM; Earle CC
    PLoS One; 2017; 12(10):e0185198. PubMed ID: 29016627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
    Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
    Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
    Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
    Ohki T; Kondo M; Karasawa Y; Kawamura S; Maeshima S; Kojima K; Seki M; Toda N; Shioda Y; Tagawa K
    Adv Ther; 2017 May; 34(5):1097-1108. PubMed ID: 28389996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Yang M; Yuan JQ; Bai M; Han GH
    Mol Biol Rep; 2014 Oct; 41(10):6575-82. PubMed ID: 25091939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
    Fu S; Chen S; Liang C; Liu Z; Zhu Y; Li Y; Lu L
    Oncotarget; 2017 Jun; 8(23):37855-37865. PubMed ID: 27911268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
    Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
    Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
    Ye HH; Ye JZ; Xie ZB; Peng YC; Chen J; Ma L; Bai T; Chen JZ; Lu Z; Qin HG; Xiang BD; Li LQ
    World J Gastroenterol; 2016 Apr; 22(13):3632-43. PubMed ID: 27053855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
    Yao X; Yan D; Zeng H; Liu D; Li H
    J Surg Oncol; 2016 May; 113(6):672-7. PubMed ID: 26989044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Ho JC; Hsieh ML; Chuang PH; Hsieh VC
    Value Health Reg Issues; 2018 May; 15():120-126. PubMed ID: 29704658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.
    Takano M; Kokudo T; Miyazaki Y; Kageyama Y; Takahashi A; Amikura K; Sakamoto H
    World J Gastroenterol; 2016 Nov; 22(42):9445-9450. PubMed ID: 27895433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
    Leung HW; Liu CF; Chan AL
    Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
    Geschwind JF; Kudo M; Marrero JA; Venook AP; Chen XP; Bronowicki JP; Dagher L; Furuse J; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Ye SL; Yoon SK; Nakajima K; Lehr R; Heldner S; Lencioni R
    Radiology; 2016 May; 279(2):630-40. PubMed ID: 26744927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Rognoni C; Ciani O; Sommariva S; Tarricone R
    Value Health; 2017 Mar; 20(3):336-344. PubMed ID: 28292478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
    Liu F; Meng Z; Shao G; Wang J; Wang Z; Yang J; Yip CS; He D
    Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.